Market Closed -
OTC Markets
12:31:05 01/06/2024 am IST
|
5-day change
|
1st Jan Change
|
0.0004
USD
|
-.--%
|
|
-.--%
|
+33.33%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
0.75
|
1.95
|
5.841
|
0.5884
|
0.543
|
Enterprise Value (EV)
1 |
0.7488
|
2.146
|
6.03
|
0.9498
|
1.102
|
P/E ratio
|
-125
x
|
-11
x
|
-12
x
|
-0.74
x
|
-1.86
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
49,36,64,304
x
|
83,17,50,641
x
|
25,21,90,742
x
|
36,31,197
x
|
EV / Revenue
|
-
|
54,33,44,810
x
|
85,86,60,496
x
|
40,71,13,588
x
|
73,67,338
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-73,03,838
x
|
EV / FCF
|
-
|
-3,23,47,802
x
|
-3,13,26,545
x
|
4,95,43,373
x
|
-1,44,53,489
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
0%
|
-0%
|
Price to Book
|
-29.4
x
|
-9.58
x
|
-18.9
x
|
-0.88
x
|
-0.7
x
|
Nbr of stocks (in thousands)
|
4,99,994
|
4,99,994
|
5,24,994
|
6,53,735
|
18,09,875
|
Reference price
2 |
0.001500
|
0.003900
|
0.0111
|
0.000900
|
0.000300
|
Announcement Date
|
29/10/21
|
29/10/21
|
02/05/22
|
10/05/23
|
07/05/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
0.00395
|
0.007022
|
0.002333
|
0.1495
|
EBITDA
|
-
|
-
|
-
|
-
|
-0.1508
|
EBIT
1 |
-0.00622
|
-0.1775
|
-0.3133
|
-0.603
|
-0.1658
|
Operating Margin
|
-
|
-4,494.86%
|
-4,461.83%
|
-25,846.38%
|
-110.9%
|
Earnings before Tax (EBT)
1 |
-0.00622
|
-0.1778
|
-0.4752
|
-0.7612
|
-0.2066
|
Net income
1 |
-0.00622
|
-0.1778
|
-0.4752
|
-0.7612
|
-0.2101
|
Net margin
|
-
|
-4,502.23%
|
-6,767.92%
|
-32,626.88%
|
-140.52%
|
EPS
2 |
-0.000012
|
-0.000355
|
-0.000926
|
-0.001224
|
-0.000161
|
Free Cash Flow
|
-
|
-0.0663
|
-0.1925
|
0.0192
|
-0.0762
|
FCF margin
|
-
|
-1,679.7%
|
-2,741%
|
821.73%
|
-50.97%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/10/21
|
29/10/21
|
02/05/22
|
10/05/23
|
07/05/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
0.2
|
0.19
|
0.36
|
0.56
|
Net Cash position
1 |
0
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-3.704
x
|
Free Cash Flow
|
-
|
-0.07
|
-0.19
|
0.02
|
-0.08
|
ROE (net income / shareholders' equity)
|
-
|
155%
|
178%
|
147%
|
27.8%
|
ROA (Net income/ Total Assets)
|
-
|
-157%
|
-122%
|
-375%
|
-101%
|
Assets
1 |
-
|
0.1133
|
0.3911
|
0.2029
|
0.2075
|
Book Value Per Share
2 |
-0
|
-0
|
-0
|
-0
|
-0
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0
|
0
|
Capex
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/10/21
|
29/10/21
|
02/05/22
|
10/05/23
|
07/05/24
|
|
1st Jan change
|
Capi.
|
---|
| +33.33% | 1.2M | | +40.73% | 734B | | +32.83% | 591B | | -6.30% | 350B | | +15.15% | 315B | | +4.05% | 276B | | +15.00% | 238B | | +9.78% | 206B | | -5.52% | 204B | | +6.17% | 161B |
Other Pharmaceuticals
|